Shusuke Kawashima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shusuke Kawashima has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Inozume
Department of Dermatology, Graduate School of Medicine Chiba University Chiba Japan
101 shared publications - Masahito Kawazu
Division of Cell Therapy Chiba Cancer Center Chiba Japan
100 shared publications - Yosuke Togashi
Department of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan
100 shared publications - Joji Nagasaki
Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
85 shared publications - Takao Morinaga
Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan
85 shared publications - Tatsuyoshi Kawamura
Department of Dermatology, University of Yamanashi
74 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
LAG3, HAVCR2, TIGIT, TNFRSF9, ENTPD1, and ITGAE expression using our scRNA-seq data and volcano plots (exhausted CD8+ T-cell vs. the others) using the publicly available datasets
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
LAG3, HAVCR2, TIGIT, TNFRSF9, ENTPD1, and ITGAE expression using our scRNA-seq data and volcano plots (exhausted CD8+ T-cell vs. the others) using the publicly available datasets
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
TableS1 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Patient characteristics for scRNA/TCR-seq or flow cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTableS1 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Patient characteristics for scRNA/TCR-seq or flow cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 functional analysis data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 functional analysis data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 expression data in PBMCs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Additional CD106 expression data in PBMCs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Differentially expressed genes between the exhausted CD8+ T cells and the others
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Differentially expressed genes between the exhausted CD8+ T cells and the others
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
TableS3 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Summary of the antibodies used in flow cytometry analyses
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTableS3 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Summary of the antibodies used in flow cytometry analyses
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Influence of CD106 on various surface molecules
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Influence of CD106 on various surface molecules